IACH Symposium at ASH 2026

Anti-BCMA bispecific antibodies in multiple myeloma: from biology to real-world implementation

This activity is approved for AMA PRA Category 1 Credit™

Register today

In Joint Providership with

American University of Beirut Faculty of Medicine and Healthcare Professional Development Center
Friday, December 11, 2026 07:00–10:00AM CT Great Hall A-D In person + virtual

Date

Friday, December 11, 2026

Time

07:00–10:00AM CT

Location

Great Hall A-D

Format

In person + virtual

General Information

A clinically focused overview of anti-BCMA bispecific antibodies in multiple myeloma, spanning from biological foundations to real-world implementation. International experts will review the mechanisms of BCMA targeting and T-cell engagement, highlighting key pathways of response and resistance. The program will then examine pivotal clinical trial data in relapsed/refractory disease, followed by emerging evidence supporting earlier use in the treatment paradigm.

This dedicated symposium will explore real-world outcomes, emphasizing differences from clinical trials and the importance of patient selection. Practical aspects of care will be addressed, including out-patient administration models, step-up dosing strategies, and multidisciplinary coordination. Particular attention will be given to toxicity management, with a strong focus on infection risk, prevention strategies, and long-term immune suppression associated with bispecific therapies. We will conclude with an interactive clinical case discussion, allowing participants to apply evidence-based decision-making to real-life scenarios, including sequencing with CAR-T therapies and management of complex patients. This program aims to equip clinicians with actionable insights to optimize the safe and effective integration of bispecific antibodies into routine myeloma care.

At the end of this symposium, participants will be able to:

  • Explain the biological rationale of anti-BCMA bispecific antibodies, including mechanisms of action, immune engagement, and resistance pathways.
  • Interpret key clinical trial data evaluating anti-BCMA bispecific antibodies in relapsed/refractory multiple myeloma, including efficacy and safety outcomes.
  • Assess the evolving role of bispecific antibodies in earlier lines of therapy and their positioning relative to other BCMA-targeted approaches such as CAR-T cells.
  • Evaluate real-world evidence to inform patient selection, expected outcomes, and management strategies outside of clinical trials.
  • Implement practical strategies for outpatient administration, including patient monitoring, step-up dosing logistics, and multidisciplinary coordination.
  • Recognize and manage the toxicities of bispecific therapy, including cytokine release syndrome, neurotoxicity, and infectious complications, with prophylaxis and immunoglobulin replacement where indicated.
  • Apply evidence-based decision-making to complex real-life cases, including sequencing with CAR-T therapies and treatment after BCMA-directed therapy.

This symposium is designed for hematologists and medical oncologists, in academic and community practice, who manage patients with multiple myeloma across the disease continuum and are integrating anti-BCMA bispecific antibodies into routine care. It is also intended for transplant and cellular therapy specialists involved in sequencing decisions between bispecific antibodies and CAR-T therapies; advanced practitioners, including nurse practitioners, physician associates, and oncology nurses, who manage patients on these therapies day to day; oncology pharmacists; infectious disease specialists; and hematology and oncology fellows and trainees.

Date

Friday, December 11, 2026

Time

07:00–10:00AM Central Time

Location

Ernest N. Morial Convention CenterGreat Hall A-D900 Convention Center Blvd.New Orleans, LA 70130

Format

In person + virtual

Prof. Mohamad Mohty

Prof. Mohamad Mohty

Activity director · Paris, France

Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myélome (IFM).

In addition to publishing more than 900 peer reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor in Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals.

Accreditation Statement

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the American University of Beirut Medical Center (AUBMC). The Healthcare Professional Development Center (HPDC) at AUBMC is accredited by the ACCME to provide continuing medical education for physicians.

The Healthcare Professional Development Center at AUBMC designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Evaluation Form and CME Certificate

The evaluation and the ability to claim CME credits will be available online approximately 10 working days after the event. An e-mail from AUBMC HPDC will be sent to you with instructions for claiming AMA PRA Category 1 Credits™, and you will have 60 days following the activity to claim credits.

Important Notes

The same e-mail address which was used for registration and where you receive the e-mail and instructions from AUBMC HPDC will need to be used in order to claim credits.

Faculty Disclosure

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education issued by the Accreditation Council for Continuing Medical Education (ACCME), the Healthcare Professional Development Center at AUBMC requires the identification, mitigation and disclosure of all faculty financial relationships with ineligible companies to ensure CME activities are free of commercial bias.

The following faculty have indicated that they have a relevant financial relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Name Company Relation
Dr. Mohamad Mohty Amgen Lecture fees
Janssen Lecture fees and advisory board
Takeda Lecture fees
Sanofi Lecture fees and advisory board
GSK Lecture fees and advisory boards
Menarini Lecture fees and advisory boards
Pfizer Lecture fees and advisory boards
BMS Lecture fees and advisory boards
Dr. Karthik Ramasamy AstraZeneca Honoraria
Adaptive Biotech Honoraria and advisory board
Bristol Myers Squibb Honoraria, research, and advisory board
Amgen Honoraria
GSK Honoraria, research, and advisory board
Johnson and Johnson Honoraria, research, and advisory board
Menarini Stemline Honoraria and advisory board
Pfizer Honoraria, research, and advisory board
Sanofi Honoraria, research, and advisory board
Takeda Honoraria
Dr. Elena Zamagni Janssen Honoraria and advisory role
Bristol-Myers Squibb Honoraria and advisory role
Sanofi Honoraria and advisory role
Amgen Honoraria and advisory role
GlaxoSmithKline Honoraria and advisory role
Pfizer Honoraria and advisory role
Oncopeptides Honoraria and advisory role
Menarini-Stemline Honoraria and advisory role
Roche Honoraria and advisory role
AstraZeneca Honoraria and advisory role

The rest of the faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest.

Why Attend

Three hours

Seven international experts

Practical answers for the bispecific era

Review the latest anti-BCMA bispecific data and discuss how to translate it into real-world practice, including sequencing with CAR-T, earlier-line use, outpatient administration, toxicity and infection management, and treatment after BCMA-directed therapy.

Speakers

Prof. Mohamad Mohty

Mohamad Mohty

France

Prof. Maria-Victoria Mateos

Maria-Victoria Mateos

Spain

Prof. Nizar Bahlis

Nizar Bahlis

Canada

Prof. Salomon Manier

Salomon Manier

France

Prof. Karthik Ramasamy

Karthik Ramasamy

UK

Prof. Elena Zamagni

Elena Zamagni

Italy

Prof. Douglas W. Sborov

Douglas W. Sborov

USA

Agenda

07:00–07:30

Welcome

07:30–07:35

Overview of objectives and agenda

Mohamad Mohty (France), Maria-Victoria Mateos (Spain)

07:35–08:00

Session 1Biology of Anti-BCMA bispecific antibodies

Presentation20 min

Redirecting immunity: BCMA targeting and T-cell engagement

Nizar Bahlis (Canada)

Q&A5 min

08:00–08:25

Session 2Clinical trial data in late relapse (RRMM)

Presentation20 min

Efficacy and safety of anti-BCMA bispecifics in triple-class refractory myeloma

Maria-Victoria Mateos (Spain)

Q&A5 min

08:25–08:50

Session 3Moving earlier: bispecifics in frontline and early relapse

Presentation20 min

Should bispecifics move to earlier lines of therapy?

Salomon Manier (France)

Q&A5 min

08:50–09:15

Session 4Real-world evidence

Presentation20 min

From clinical trials to daily practice: real-world outcomes and challenges

Karthik Ramasamy (UK)

Q&A5 min

09:15–09:40

Session 5Outpatient administration and toxicity management

Presentation20 min

Delivering bispecifics safely: outpatient models, CRS/ICANS management, and infection prevention

Elena Zamagni (Italy)

Q&A5 min

09:40–09:55

Session 6Extended interactive clinical case discussions

Real-life decision making in the era of bispecifics

Multiple cases with live polling and panel interaction

PresenterMohamad Mohty (France)

PanelistDouglas W. Sborov (USA)

Focus on

Sequencing (CAR-T vs bispecifics)

Early relapse strategies

Infection management and treatment interruptions

Post-BCMA relapse

09:55–10:00

Final expert panel discussion with all speakers and moderators & key take-home messages

Rapid-fire conclusions

Audience Q&A (if time allows)

Symposium Registration

How would you like to attend? *